NDAINTRAVENOUSPOWDER
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3
Data completeness
5/8 — Partial
UPTRAVI (selexipag) by Johnson & Johnson is prostacyclin receptor agonists [moa]. Approved for pulmonary hypertension. First approved in 2021.
Drug data last refreshed Yesterday
Mechanism of Action
Prostacyclin Receptor Agonists
Pharmacologic Class:
Prostacyclin Receptor Agonist
Indications (1)
Clinical Trials (3)
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Started Oct 2020
20 enrolled
Pulmonary HypertensionSchistosomiasis
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Started Oct 2020
372 enrolled
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Started May 2017
0Pulmonary Arterial Hypertension
Worked on UPTRAVI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.